News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Regeneron Pharmaceuticals, Inc. Drug to Lower Gout Flares Meets Goal in Study
September 3, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Sept 3 (Reuters) - Regeneron Pharmaceuticals Inc said a mid-stage study of its experimental treatment for gout, Arcalyst, met the main goal and reduced the incidence of gout flares by 81 percent.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Regeneron Pharmaceuticals, Inc.
MORE ON THIS TOPIC
Bladder cancer
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
March 2, 2026
·
2 min read
·
Tristan Manalac
Insights
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
February 26, 2026
·
1 min read
·
Jennifer Smith-Parker
Diabetes
Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front
February 26, 2026
·
2 min read
·
Annalee Armstrong
HIV
Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data
February 26, 2026
·
2 min read
·
Tristan Manalac